Kyorin Pharmaceutical

The Ogihara family maintains control through a network of holding companies, with Mykam Co., Ltd. holding roughly 8.5%, Lucius Co., Ltd. about 4.84%, and additional stakes held by Banrina, Archans, and Luces. CEO Yutaka Ogihara is the most senior named principal, alongside Ikuo Ogihara and Hiroko Ogihara, who also leads Apricot Co., Ltd., a spinout of the family asset management operations. This multi-entity arrangement suggests family wealth is deliberately divided across vehicles rather than pooled in a single family office.

It is fundamentally an operating company — a publicly listed pharmaceutical developer, manufacturer, and marketer. The Ogihara family does not market investment services or manage third-party capital. However, the concentration of family ownership through multiple holding companies and the firm's direct balance-sheet investment in real estate and R&D infrastructure give it the de facto characteristics of a single-family investment vehicle housed inside a corporate structure.

Kyorin's non-pharma deployment is concentrated in commercial real estate, with direct ownership of Tokyo properties including its head office at Ochanomizu Sola City, the Kyorin Nishi-Shinjuku Building, and an interest in the Nikkei Tokyo Head Office Building. There is no public evidence of external fund commitments, venture allocations, or third-party manager relationships. The firm appears to reinvest surplus cash flow into both its drug pipeline and hard assets it controls directly.

The Anzu no Mori Foundation is the family's documented philanthropic vehicle, maintained as a separate general incorporated foundation. This separation of charitable and corporate capital is consistent with the Ogihara family's broader pattern of partitioning assets across distinct legal entities rather than consolidating them under a single family-office umbrella.

Kyorin's disclosed asset footprint is entirely domestic, spanning pharmaceutical plants in Akita, Toyama, and Shiga prefectures, a research center in Tochigi, and commercial properties concentrated in Tokyo. The firm's 2025 membership in CCI France Japon may signal exploratory commercial or scientific interest in France, though no cross-border investments, subsidiaries, or joint ventures have been publicly confirmed.